Rocketman

GILD: Triangle Within A Triangle Plus Volume

Long
Rocketman Updated   
NASDAQ:GILD   Gilead Sciences, Inc.
FUNDAMENTALS:
GILD ( Gilead Sciences ) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
***Revenue is also generated when more people catch and/or are dying of covid with their covid treatment called Veklury. Revenue soared around $1.5 billion from Veklury alone.

Target 80 or 165

Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.